Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEDICAID COST SAVINGS THROUGH DRUG MANUFACTURER REBATES

Executive Summary

State Medicaid agencies can achieve savings by obtaining price rebates directly from manufacturers, under a proposal floated by Sen. Pryor (D-Ark.) on March 20. Pre-negotiated discounts are based on a percentage of products' wholesale acquisition cost, according to the payment plan, excerpted below from the legislation. Rebates from manufacturers: Each state medical Assistance agency shall periodically obtain a rebate from each manufacturer with whom negotiations were successful, in an amount calculated as the product of - * the documented number of tablets or other dosage form units of the manufacturer's prescription drug which has been dispensed to qualified beneficiaries of the state medical assistance program, and * the difference between the negotiated per tablet or other dosage unit price and the per tablet or per unit wholesale acquisition price. State reliance on National Pharmacy and Therapeutics Committee Determinations: The state medical assistance plan shall (except states grandfathered under Section 5(a)(5)) incorporate by reference the determinations of the National Pharmacy and Therapeutics Committee with respect to which prescription drugs are - * medically accepted for a given therapeutic indication, and * equally safe and effective therapeutic alternatives. Access to drug therapies guaranteed: The State medical assistance plan shall provide that at least one drug in every group of equally safe and effective therapeutic alternatives is covered and reimbursable as a preferred drug.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017163

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel